Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies (SCLERONAB)

Central Hospital, Nancy, France

Status

Not yet enrolling

Conditions

Systemic Sclerosis

Treatments

Other: disease phenotype

Study type

Observational

Funder types

Other

Identifiers

NCT06412614

2024PI015

Details and patient eligibility

About

Systemic sclerosis (SSc) is a complex systemic autoimmune disease with variable phenotype and prognosis. Autoantibodies are important diagnostic biomarkers in SSc. More than 90% of patients with SSc had anti-nuclear antibodies. Autoantibodies specific to SSc (anti-topoisomerase I antibodies, anti-centromeres, anti-RNA polymerase III, anti-Th/To, anti-fibrillarin, anti-NOR90) or associated with overlap syndromes (anti-RNA polymerase III antibodies -PM/Scl, anti-KU, anti-U1RNP, anti-TRIM21) are detected in most patients. Excluding anti-TRIM21 antibodies, autoantibodies are usually mutually exclusive and are associated with distinct phenotypes.

Around 5 to 10% of patients with SSc have no autoantibodies detectable with routine biological tests. Recently, new autoantibody specificities have been described in SSc (anti-eIF2B, anti-RuvBL1/2, anti-BICD2, anti-U11/U12 RNP antibodies).

"Seronegative" patients could represent new specificities of autoantibodies (unknown or not currently routinely evaluated) associated with different phenotypes of the disease.

Primary objective is to compare the phenotype of patients with systemic sclerosis with or without detectable specific or associated autoantibodies.

Secondary objectives are:

to determine homogeneous groups of patients with systemic sclerosis without detectable specific or associated autoantibodies
to compare the phenotype of patients with systemic sclerosis without detectable specific or associated autoantibodies according to anti-nuclear antibodies status

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with systemic sclerosis defined according to ACR/EULAR 2013 classification criteria
Patient with a minimum follow-up of 3 years since the diagnosis of systemic sclerosis
Patient evaluated for the following systemic sclerosis specific and/or associated autoantibodies: anti-topoisomerase I, anti-centromere, anti-RNA polymerase III (RP155 and RP11), anti-Th/To antibodies , anti-fibrillarin, anti-NOR90, anti-PM/Scl, anti-KU, anti-U1RNP and anti-SSA antibodies (independently of antinuclear antibodies status)

Exclusion criteria

Patient with equivocal results for one or more systemic sclerosis specific and/or associated autoantibodies
Patient initially negative but with a positive result for systemic sclerosis specific and/or associated autoantibodies during follow-up